Table 2.

Coprimary endpoints at week 12 (ITT population)

	IDP-126 gel (n = 146)	BPO/ADAP gel (n = 150)	CLIN/BPO gel (n = 146)	CLIN/ADAP gel (n = 150)	Vehicle gel (n = 148)
Treatment successa, %	52.5	27.8***	30.5***	30.3***	8.1***
Absolute change from baseline, LS mean
Inflammatory lesions	− 29.9	− 26.7*	− 24.8**	− 26.8*	− 19.6***
Noninflammatory lesions	− 35.5	− 29.9**	− 27.8***	− 30.0**	− 21.8***

Multiple imputation was used to impute missing values

ADAP adapalene 0.15%, BPO benzoyl peroxide 3.1%, CLIN clindamycin phosphate 1.2%, EGSS Evaluator’s Global Severity Score, IDP-126 clindamycin phosphate 1.2%/benzoyl peroxide 3.1%/adapalene 0.15%, ITT intent to treat, LS least squares

*P < 0.05; **P < 0.01; ***P ≤ 0.001 vs IDP-126

^aDefined as a ≥ 2-grade reduction from baseline in EGSS and a score of 0 (clear) or 1 (almost clear)